Are natriuretic peptides clinically useful as markers of heart failure?

Annals of Clinical Biochemistry

Volumn 38, Issue 2, 2001, Pages 94-102

  Kelly, R ^a   Struthers, A D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC PEPTIDE TYPE C; RECEPTOR PROTEIN;

ANALYTIC METHOD; DIAGNOSTIC VALUE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW;

EID: 0035106924     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456320103800522     Document Type: Review

References (70)

1. Atrial natriuretic peptide and its messenger ribonucleic acid in overloaded and overload-released ventricles of rat
2. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart
3. Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine
4. Physiological role of silent receptors of atrial natriuretic factor
5. Molecular biology of the natriuretic peptides and their receptors
6. Differing biological effects of equimofar atrial and brain natriuretic peptide infusions in normal man
7. Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor
8. Pressor effect of blocking atrial natriuretic in nucleus tractus solitarii
9. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells
10. C-type natriuretic peptide inhibits intimal thickening after vascular injury
11. Atrial natriuretic peptide causes pre-glomerular vasodilation and post-glomerular vasoconstriction in rat kidney
12. Natriuretic peptides
13. Failure of atriopeptin II to cause arterial vasodilation in the conscious rat
14. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites
15. The kidney in chronic liver disease: Use of natriuretic peptides
16. Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats
17. Endothelin increases atrial natriuretic peptide production in cultured rat diencephalic neurons
18. Arginine vasopressin stimulates atrial natriuretic peptide gene expression and secretion from rat hypothalamic diencephalic neurons
19. Interactions between ANP and ANG II in regulating blood pressure and sympathetic outflow
20. The C-type natriuretic peptide receptor is the predominant natriuretic peptide receptor mRNA expressed in rat hypothalamus
21. Cardiac peptide stability, aprotinin and room temperature: Importance for assessing cardiac function in clinical practice
22. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left ventricular dysfunction
23. Risk assessment of left ventricular systolic dysfunction in primary care: Cross-sectional study evaluating a range of diagnostic tests
24. Plasma atrial natriuretic peptide level as an index for the severity of congestive heart failure
25. Effect of captopril on mortality and morbidity in patients with reduced LV function after myocardial infarction
26. N-terminal proatrial natriuretic factor: An independent predictor of long-term prognosis after myocardial infarction
27. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern
28. Plasma N-terminal atrial natriuretic peptide predicts hospitalization in patients with heart failure
29. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction
30. Comparison of atrial natriuretic peptide, B-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic function
31. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment
32. Superiority of BNP as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
33. Natriuretic peptides and cGMP in asymptomatic and symptomatic left ventricular dysfunction
34. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease
35. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
36. Biochemical detection of left ventricular systolic dysfunction
37. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction
38. Plasma brain natriuretic peptide concentration as a prognostic predictor in patients with chronic congestive heart failure
39. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure
40. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction
41. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction
42. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long term survival after acute myocardial infarction
43. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: Influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation
44. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction
45. Cosecretion of atrial and brain natriuretic peptides stimulated by endothelin-I from cultured rat atrial and ventricular cardiocytes
46. Plasma endothelin in chronic heart failure
47. Detection of left ventricular dysfunction after acute myocardial infarction: Comparison of clinical, echocardiographic and neurohormonal methods
48. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
49. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left ventricular systolic dysfunction in a high risk population
50. Effect of ACE inhibitors on the atrial natriuretic peptides in heart failure
51. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure
52. Effects of low dose betablockers on atrial and ventricular (B-type) natriuretic factor in heart failure: A double blind, randomised comparison of metoprolol and a third generation vasodilating betablocker
53. Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure
54. A rapid bedside test for brain natriuretic peptide accurately predicts cardiac function in patients referred for echocardiography
55. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy
56. How to use natriuretic peptides levels for diagnosis and prognosis
57. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy
58. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction
59. Should we screen for treatable left ventricular systolic dysfunction in patients who present with their first stroke, transient ischaemic attack or peripheral vascular disease?
60. How well can the chest radiograph diagnose left ventricular dysfunction?
61. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
62. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N-terminal pro-BNP
63. Stabilization of human brain natriuretic peptide in blood samples
64. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice
65. N-terminal pro-ANP and BNP are stable for up to 6 hours in whole blood in vitro
66. Measurement and significance of circulating natriuretic peptides in cardiovascular disease
67. Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (BNP) concentrations
68. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
69. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to the left ventricular end-systolic wall stress in patients with aortic stenosis
70. Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation